Individual studies offer clues. A review asks how those clues fit together.
What the review examined
Miyako Tazaki reviewed research on neurofeedback in mild cognitive impairment and Alzheimer’s disease. The abstract identifies 13 relevant articles. This was a review of existing work, not a new treatment trial.
A promising but varied picture
Across the literature, researchers reported improvements in memory, attention, and other cognitive abilities. However, studies used different training protocols, electrode locations, session schedules, and outcome measures. Those differences make it difficult to compare results or identify a single approach that works best.
Why stronger studies matter
The review calls for larger samples and more rigorous methods, including better control of placebo effects and factors such as medications and disease severity. The findings support continued investigation. They do not establish a cure, a reliable way to prevent Alzheimer’s disease, or a guaranteed benefit for an individual.
Tazaki M. A review: effects of neurofeedback on patients with mild cognitive impairment (MCI), and Alzheimer’s disease (AD). Front Hum Neurosci. 2024;17:1331436. doi:10.3389/fnhum.2023.1331436.
Read the original research →